Beneficient (BENFW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-10

Key Insights

Beneficient acquired a limited partner interest in an investment fund valued at $8.75 million, issuing 875,214 shares of its Series B-10 Resettable Convertible Preferred Stock in exchange.
The Series B-10 Preferred Stock has a conversion price that is subject to reset each month, with a floor price of $1.2418 per share.
Beneficient participates in an unrealized gain of $1.2 million from the appreciation of the customer's existing asset portfolio as part of this transaction.

Want the newest filings?

This analysis covers the filing from 2026-04-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-30

Beneficient, an emerging growth company, has amended its 2023 Long Term Incentive Plan to increase the number of shares reserved for issuance, indicating a focus on employee incentives and retention.
Shareholders overwhelmingly approved the LTIP amendment, with over 91% of voting power represented at the annual meeting, suggesting broad investor support.
The company's leadership team remains stable, with the reelection of all Class A directors, providing continuity in the company's strategic direction.

Filed: 2026-03-12

Beneficient has repaid the outstanding principal amount of $27.5 million on its credit facility with HH-BDH, LLC prior to the stated maturity date.
Beneficient has agreed to issue 149,904 shares of its Class A common stock to HH-BDH in exchange for the remaining $1.66 million in interest and fees owed under the credit facility.
Beneficient has appointed Mack Hicks, CEO of Hicks Holdings, to its board of directors in connection with the Stockholders Agreement.

Filed: 2026-02-17

Beneficient, an emerging growth company, reported its Q3 2025 financial results, indicating continued growth and progress.
The company's common stock and warrants are traded on the Nasdaq exchange, providing public market access for investors.
As an emerging growth company, Beneficient has the option to use the extended transition period for complying with new or revised financial accounting standards, which could impact financial reporting and transparency.

Filed: 2026-01-08

Beneficient, an emerging growth company, filed an 8-K disclosure on a Series B-9 primary capital transaction involving the issuance of 302,273 shares of Series B-9 Resettable Convertible Preferred Stock to a customer in exchange for a limited partner interest in an investment fund.
The Series B-9 Preferred Stock is convertible into Beneficient's Class A Common Stock at an initial conversion price of $7.1332 per share, subject to periodic reset adjustments with a floor of $5.3499 per share.
The transaction was not registered under the Securities Act and was issued in reliance on the exemption under Section 4(a)(2) and Regulation D, potentially indicating strategic or private financing arrangements.

Other reports for Beneficient

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.